Arecor Therapeutics Share Discussion Threads

[supernumerary] 06/4/2022 08:23

It's so illiquid I don't see how anyone could trade it. Or buy in reasonable quantity.

[jimbo123elf] 06/4/2022 08:04

I agree i'm glad this stock is largely free from traders. I'd much rather have a shareholder base of serious investors who really understand the company and its pioneering science. Our current significant shareholders BGF, Unilever, Calculus, Downing, Albion, Chelverton, Unicorn and Amati know exactly why they are here.

[stupidboypike] 06/4/2022 07:55

alloa, thank goodness I think Arecor shares are relatively free from traders. I'm not expecting any surprises (good or bad) on 25th, it's not like their sales (or costs) will have suddenly changed from expectations. Next news we are expecting is progress on the Hikma deal sometime in H1 2022, then news on the AT247 trial which completes H2 2022. In my view this is not a share for traders, but long term serious investors.

Best regards SBP

[alloa2003] 06/4/2022 07:14

Will we see some short term traders taking a position on the results/update on 25th April?

[sharesoc] 31/3/2022 23:39

In case you missed our webinar with Arecor Therapeutics (AREC), the recording can be found on our YouTube channel:

[alloa2003] 29/3/2022 07:18

This share seems to be flying under the radar of many investors which is a shame as it seems to have a lot to offer.

[alloa2003] 29/3/2022 07:14

Will we see traders jump onboard ahead of the full year results on:-

Monday 25 April 2022

It wont take much buying to move this stock!

[jimbo123elf] 28/3/2022 23:15

Bendamustine is used to treat chronic lymphocytic leukaemia (CLL), non-Hodgkin lymphoma (NHL) and myeloma.

[stupidboypike] 28/3/2022 20:16

Thanks jimbo. Best regards SBP

[stupidboypike] 28/3/2022 17:53

Jimbo, do you have a link to that info? Can’t find it. Best regards SBP

[jimbo123elf] 28/3/2022 17:33

Seems they have filed for a new patent related to chemo medication Bendamustine.

[jimbo123elf] 28/3/2022 16:45

Good news indeed on the company and CEO awards.

[alloa2003] 28/3/2022 12:18

Interest seems to be growing after a quiet period. The award over the weekend keeps the company in the news.

[alloa2003] 25/3/2022 15:26

Edging higher

[alloa2003] 23/3/2022 07:38

Nice progress:-

ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS



Further strengthens the Company's extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio



Cambridge, UK, 23 March 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11278624) protecting novel formulations of the Group's proprietary insulin products, AT247 and AT278.



Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "Arecor's novel insulin products, based on a combination of existing insulin analogues and our highly innovative formulation science, have potential to improve convenience, compliance and enable more effective management of blood glucose for people living with type 1 and type 2 diabetes. As the clinical validation of the superiority of these products compared to current gold standard prandial insulins continues, we are also advancing the intellectual property protection for these products. This recently granted US patent, the first within the Group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress."



Arecor has invested in building a strong patent portfolio to protect the Arestat™ technology platform and its proprietary pipeline products. The Group's intellectual property (IP) portfolio currently comprises 36 patent families, including >50 granted patents in Europe, the US and in other key territories. As part of this strategy, Arecor has robust IP directed to the novel insulin compositions that protect different aspects of AT247 and AT278 formulations, as well as their specific properties and methods of use. Arecor's strategy is to generate a fortress of both narrow and broad interrelated IP rights that cover the features of these products. US11278624 is the first granted US patent within the Group's comprehensive insulin IP strategy.

[alloa2003] 21/3/2022 16:03

A trickle of interest

[timbo003] 15/3/2022 19:14

Thanks SBP, exciting times ahead by the sounds of it and all relatively low risk (for a Pharma)

...and thanks to Paul and ShareSoc for hosting the meeting 🙂

[stupidboypike] 15/3/2022 18:39

the market makers are both buying and selling well within the spread. Best regards SBP

[alloa2003] 15/3/2022 18:34

Very interesting Webinar, thanks for hosting.

Only wish the shares were a little more liquid which would encourage a tighter spread.

[donald pond] 15/3/2022 18:06

Good questions. First I'd heard of this company but definitely merits further research.

[stupidboypike] 15/3/2022 18:04

Great presentation thanks Donald. Timbo - great questions thanks - saved me asking any - I just voted yours up!! Best regards SBP

[donald pond] 15/3/2022 12:04

I'm going to be hosting it, get your questions ready

[alloa2003] 15/3/2022 08:06

Should be an interesting webinar tonight.

[sharesoc] 02/3/2022 21:24

We are hosting a webinar with Arecor Therapeutics plc (AREC) on 15 March 2022, which may be of interest to current shareholders or potential investors. Sarah Howell (Chief Executive Officer) will be presenting. You can register here: